Alignment Healthcare CEO sells 557,870 shares

Alignment Healthcare, Inc. (ALHC) reported that Chief Executive Officer and director John E. Kao disclosed two sales of common stock totaling 557,870 shares.

Rhea-AI Filing Summary

Alignment Healthcare, Inc. (ALHC) reported that Chief Executive Officer and director John E. Kao disclosed two sales of common stock totaling 557,870 shares.

On September 11, 2026, Kao sold 385,270 shares at a weighted-average price of $12.68 per share, in multiple trades between $12.394 and $13.17, to cover tax withholding obligations arising from the vesting of restricted stock units; the filing states this was not a discretionary trade. After this sale, he held 1,223,473 shares directly.

On September 10, 2026, a trust associated with Kao, the JEK Trust dated February 8, 2021, sold 172,600 shares at a weighted-average price of $12.96 per share, in trades between $12.71 and $13.21, under a Rule 10b5-1 trading plan adopted on May 27, 2026. These shares are reported as held indirectly, with 618,166 shares remaining in the trust after the transaction.

Insider Trade Summary 10b5-1

Net Seller: 557,870 shares

Net Sell 2 txns

Insider KAO JOHN E

Role Chief Executive Officer

Sold 557,870 shs ($7.12M)

Type	Security	Shares	Price	Value
Sale	Common Stock F4, F5	385,270	$12.68	$4.89M
Sale	Common Stock F1, F2, F3	172,600	$12.9574	$2.24M

Holdings After Transaction: Common Stock — 618,166 shares (Indirect, See Footnote); Common Stock — 1,223,473 shares (Direct)

Footnotes (5)

1. F1. Date of Rule 10b5-1 plan adoption: 05/27/2026
2. F2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $12.71 to $13.21. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.
3. F3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.
4. F4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This transaction does not represent a discretionary trade by the reporting person.
5. F5. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $12.394 to $13.17. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Key Figures

Total shares sold: 557,870 shares Shares sold to cover tax withholding: 385,270 shares Weighted-average sale price (tax-withholding sale): $12.68 per share +5 more

8 metrics

Total shares sold 557,870 shares Combined sales of ALHC common stock reported on this Form 4

Shares sold to cover tax withholding 385,270 shares Sale on September 11, 2026 related to RSU tax withholding obligations

Weighted-average sale price (tax-withholding sale) $12.68 per share September 11, 2026 sale, price range $12.394 to $13.17

Direct holdings after tax-withholding sale 1,223,473 shares Direct ALHC common stock owned by John E. Kao after September 11, 2026

Shares sold under Rule 10b5-1 plan 172,600 shares JEK Trust sale on September 10, 2026 under plan adopted May 27, 2026

Weighted-average sale price (JEK Trust sale) $12.96 per share September 10, 2026 sale, price range $12.71 to $13.21

Indirect holdings after trust sale 618,166 shares ALHC shares held by JEK Trust, for which Kao is trustee, after September 10, 2026

Rule 10b5-1 plan adoption date May 27, 2026 Date of trading plan covering the September 10, 2026 JEK Trust sale

Key Terms

Rule 10b5-1 plan, weighted-average price, restricted stock units, tax withholding obligations, +1 more

5 terms

Rule 10b5-1 plan regulatory

"Date of Rule 10b5-1 plan adoption: 05/27/2026"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

weighted-average price financial

"The reported price in column 4 is a weighted-average price."

Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.

restricted stock units financial

"in connection with the vesting of restricted stock units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"sold by the reporting person to cover tax withholding obligations"

indirect ownership financial

"Represents securities held by JEK Trust, of which Mr. Kao is the trustee."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ALHC CEO John E. Kao report on this Form 4?

John E. Kao reported two sales of Alignment Healthcare (ALHC) common stock totaling 557,870 shares, one from his direct holdings and one from shares held indirectly through the JEK Trust dated February 8, 2021.

How many ALHC shares did the CEO sell on September 11, 2026 and at what price?

On September 11, 2026, John E. Kao sold 385,270 ALHC shares at a weighted-average price of $12.68 per share, with individual trade prices ranging from $12.394 to $13.17, to cover tax withholding obligations from vesting restricted stock units.

How many ALHC shares did the JEK Trust sell and under what plan?

On September 10, 2026, the JEK Trust, for which John E. Kao is trustee, sold 172,600 ALHC shares at a weighted-average price of $12.96, in a range of $12.71 to $13.21, under a Rule 10b5-1 plan adopted on May 27, 2026.

How many ALHC shares does the CEO hold directly after these transactions?

After the September 11, 2026 sale, John E. Kao is reported as holding 1,223,473 ALHC shares directly. This figure reflects his direct ownership position following the tax-withholding-related sale of 385,270 shares.

What are the CEO’s indirect ALHC holdings through the JEK Trust after the sale?

Following the September 10, 2026 transaction, the filing reports that the JEK Trust, for which John E. Kao is trustee, holds 618,166 ALHC shares indirectly. The 172,600-share sale reduced, but did not eliminate, the trust’s holdings.

Were the reported ALHC stock sales discretionary trades by the CEO?

The 385,270-share sale on September 11, 2026 is described as required to cover tax withholding obligations from restricted stock unit vesting and “does not represent a discretionary trade.” The 172,600-share sale on September 10, 2026 was made under a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/11/2026 - 08:38 PM Accepted by SEC EDGAR 09/11/2026 - 08:38 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAO JOHN E

(Last) (First) (Middle)

1100 W. TOWN & COUNTRY RD., SUITE 1600

(Street)

ORANGE CALIFORNIA 92868

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Alignment Healthcare, Inc. [ ALHC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		S(1)		172,600	D	$12.9574(2)	618,166	I	See Footnote(3)
Common Stock	09/11/2026		S		385,270(4)	D	$12.68(5)	1,223,473	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Date of Rule 10b5-1 plan adoption: 05/27/2026

2. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $12.71 to $13.21. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

3. Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This transaction does not represent a discretionary trade by the reporting person.

5. The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $12.394 to $13.17. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

Remarks:

	/s/ Christopher J. Joyce, as Attorney-in-Fact, for John E. Kao	09/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)